Reposted by @oliolabs.bsky.socialDavid Tingley @davidtingley.bsky.social · 19/03/2025Some really cool work we've been doing @oliolabs.bsky.social. New science opens the door to better medicines. 171
oliolabs.bsky.social @oliolabs.bsky.social · 19/03/2025Check out what we're working on at Olio Labs! 70% of patients taking GLP-1's (like Ozempic) are women, but they experience >2x side effect rates than men. What is driving this difference? We combine human EMR data, mouse & rat behavior, and scRNAseq to figure it out: 141
